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Response inhibition
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Stop-signal taskIt is not yet well understood how dopaminergic therapy improves cognitive and motor function in Parkinson's
disease (PD). One possibility is that it reduces the pathological synchronization within and between the cortex
and basal ganglia, thus improving neural communication. We tested this hypothesis by recording scalp electro-
encephalography (EEG) in PD patients when On and Off medication, during a brief resting state epoch (no task),
and during performance of a stop signal task that is thought to engage two partially overlapping (or different)
frontal-basal-ganglia circuits. For resting state EEG, we measured pair-wise coherence between scalp electrodes
in several frequency bands. Consistent with previous studies, in the Off medication state, those patients with the
greatest clinical impairment had the strongest coherence, especially in the beta band, indicating pathological
over-synchronization. Dopaminergicmedication reduced this coherence. For the stop signal task, On vs. Off med-
ication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimo-
tor cortex for going, especially for those patients who showed greater clinical improvement. Thus, medication
reducedpathological coherence in beta band at rest and increased task related beta power for twopotentially dis-
sociable cortico-basal ganglia circuits. These results support the hypothesis that dopaminergic medication in PD
improves neural communication both at rest and for executive and motor function.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Parkinson's disease (PD) is associated with loss of dopaminergic
neurons in the midbrain and is characterized by motor symptoms
such as bradykinesia, rigidity and tremor (Rodriguez-Oroz et al., 2009)
and also by non-motor symptoms such as executive dysfunction,
mood and sleep disorder (Chaudhuri and Schapira, 2009; Lim and
Lang, 2010). While the classic ‘ﬁring rate model’ in PD emphasizes ex-
cessiveﬁring of basal ganglia output nuclei leading to excessive tonic in-
hibition of thalamus and cortex (Albin et al., 1989; DeLong, 1990),
researchers now favor a temporal ‘pattern model’ which emphasizes
neural oscillations. In particular, dopamine deﬁciency in PD apparently
results in excessive oscillations and also increased inter-regional
coherence especially at beta band frequencies (13–30 Hz) (Brown,
2003; DeLong and Wichmann, 2007; Weinberger et al., 2009). Such y, University of California San
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. Open access under CC BY license.pathological beta oscillations have been recorded from the subthalamic
nucleus, globus pallidus and the frontal cortex in both primate models
of PD and from PD patients undergoing surgery (reviewed by Brown,
2007; Brown and Williams, 2005).
While dopamine replacement therapy is currently the gold standard
treatment for improving motor function in PD the neural mechanisms
of improvement are still not well understood. One hypothesis is that
medication reduces the pathological oscillations and hypersynchrony
within and between the cortex and the basal ganglia, particularly in
the beta frequencies, thus improving communication within cortico-
basal ganglia circuits (Jenkinson and Brown, 2011). Here we tested
this idea by recording the scalp electroencephalogram in patients with
PD while On and Off dopaminergic medication while in the resting
state (no task) and also while performing a task that is suggested to en-
gage at least two cortico-basal ganglia circuits.
For resting state EEG, the subjects sat at rest for a few minutes with
their eyes open. We planned to compute pair-wise coherence between
scalp electrodes in the On and Off medication state and to relate the
coherence to their clinical Uniﬁed Parkinson's Disease Rating Scale
(UPDRS) scores. We aimed to replicate an earlier report of excessive
scalp coherence in patients Off medication, especially in the beta
frequency band, and especially for those with high UPDRS scores
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ing that the excessive coherence was reduced by medication. In so
doing, we set the stage for a novel comparison of resting and task-
related EEG signatures.
We used a task that engages both going and stopping (Logan and
Cowan, 1984). On each trial, subjects prepared to make a quick move-
ment to a go signal. On a minority of trials the go signal was followed
by a stop signal and the subjects tried to stop the initiated motor
response. Much research shows that going relies on a premotor/basal-
ganglia/primary motor network, while stopping relies on a predomi-
nantly right-lateralized prefrontal/premotor/basal-ganglia network
with downstream effects on M1 (Aron et al., 2007; Chambers et al.,
2009; Chikazoe, 2010; Coxon et al., 2006; Mattia et al., 2012; Mirabella
et al., 2011). EEG studies of going (movement) reveal that, during initi-
ation, beta power is suppressed and gamma power is increased; and
post-movement, there is an increased beta power over sensorimotor re-
gions (Engel and Fries, 2010; Leuthardt et al., 2004; Levine et al., 1999;
Pfurtscheller et al., 1996, 2003; Rohde et al., 2002). EEG studies of stop-
ping, show an increase in the beta power for cortical regions such as the
right inferior frontal cortex (Krämer et al., 2011; Marco-Pallarés et al.,
2008; Swann et al., 2009, 2011, 2012). Of particular relevance for the
current study, Swann et al. (2011) recorded scalp EEG in PD patients
while they performed the stop-signal task with concurrent deep
brain stimulation of the subthalamic nucleus (STN DBS). For stimula-
tion On compared to Off, they observed faster behavioral stopping as
well as increased beta band power over the right frontal cortex when
the patients stopped their response. Accordingly, we focused here on
a right frontal electrode cluster and beta frequency power as a mark-
er of the integrity of a putative cortico-basal ganglia circuit for stop-
ping action.
By performing a similar study to Swann et al. (2011), but this time
using medication rather than STN DBS, we aimed to compare the treat-
ment methods. While both treatments lead to improved clinical out-
comes, they operate by different mechanisms (Zaidel et al., 2010).
Dopaminergic therapy stimulates striatal activity and also exerts wide-
spread modulation of cortical and subcortical areas (Delfs et al., 1996;
Pötter-Nerger et al., 2012; Steiner and Kitai, 2001). DBS, by contrast,
acts more locally, by modulating the subthalamus and thus affecting
speciﬁc connected regions within the basal ganglia and the cortex
(Devergnas and Wichmann, 2011; Gradinaru et al., 2009; Mcintyre
et al., 2004). Notwithstanding these differences, it appears that dopami-
nergic therapy, like STN DBS, also reduces the pathological oscillations
and hyper-synchrony within and between the basal ganglia and cortex
(Hammond et al., 2007). Thus, our main aim here was to examine the
effect of medication on a scalp EEG signature of a cortico-basal ganglia
circuit for stopping, and to compare this with the earlier study with
STNDBS (Swann et al., 2011).We also aimed to examine a scalp EEG sig-
nature of going, and to see if medication in PD would have common or
different effects from stopping.
2. Materials and methods
2.1. Participants
Sixteen PD patients (eight females, mean age 62.6 ± 8.3 years) and
sixteenmatched controls (nine females, 63.5 ± 9.6 years) participated.
All participants were right handed. The PD patients were clinically typ-
ical, responsive to dopaminergic therapy. All had mild to moderate PD
(between stages II and III on the Hoehn and Yahr scale (Hoehn and
Yahr, 1967)). Clinical characteristics of the patients, including medica-
tions and dosages, are presented in Tables 1 and 2. The patients were
well matched with controls on age, gender and handedness, as well as
on the Mini-Mental Status Exam (MMSE) and the North American
Reading Test (NAART) (Ps N 0.2) (Table 2). However, the patients did
score higher on the Beck Depression Inventory (BDI) both On and
Off medication compared to controls (t30 = 4.25, P b 0.005 andt27 = 3.05, P b 0.01 respectively), with their scores being consistent
with a sub-clinical level of depression as is commonly seen in PD
(Table 2). Dopaminergic medication signiﬁcantly improved motor
symptoms, as measured by the motor section of the United Parkinson's
Disease Rating Scale (UPDRS III) (t15 = 4.00, P b 0.005) (Table 2)
(henceforth, referred to as UPDRS).
The patients were recruited from Scripps Clinic in La Jolla, California
and controls were recruited from the local community or were spouses
of the patients. All the participants provided written informed consent
according to an Institutional Review Board Protocol at the University
of California, San Diego.
One PDpatientwas excluded from the EEG analysis due to facial dys-
kinesia during the On medication session.
2.2. Procedure
Each patient visited the laboratory for two sessions, On and Offmed-
ication. The order of the visits was counter-balanced between patients.
For the Off session, the time between the last dose of dopaminergic
medication and the visit was 12 h or more, and for the On session, the
patients took their usual morning dose before coming for the session.
Clinical evaluations and rating scales were performed in the following
order for the sessions/days: Session 1 — handedness test (Oldﬁeld,
1971), BDI, UPDRS, MMSE and NAART; Session 2 — BDI and UPDRS.
Controls visited the laboratory once and clinical evaluations and rat-
ing scales were performed in the following order: handedness test, BDI,
MMSE and NAART.
Following these evaluations, the EEG setup and recordings began,
with the stop-signal task followed by the resting state.
2.3. Experiments
Experimental stimuli were presented on a 24 in. LCD monitor. Two
button boxes were used to collect left and right index ﬁnger responses.
Experimentswere designed usingMATLAB and the Psychophysics Tool-
box (Brainard, 1997; Pelli, 1997).
2.3.1. Resting state
EEG data were recorded for 3 min. The subjects were instructed to
relax, keep their eyes open and maintain ﬁxation on a white cross at
the center of the screen.
2.3.2. Stop-signal task
The stop-signal task (Fig. 1) was identical to an earlier study we
conducted with PD patients undergoing STN DBS (Swann et al., 2011).
Brieﬂy, every trial consisted of a ﬁxation at the center of the screen for
500 ms. A Go-trial (67% of trials) consisted of a Go signal, indicated by
a white square, appearing to the left or to the right of the ﬁxation. Sub-
jects had tomake a responsewithin 1500 ms (hold time) using their left
and right index ﬁngers. A Stop-trial (33% of trials) consisted of a Go sig-
nal (white square) appearing to the left or right as before, which turned
red after a variable delay, the stop signal delay (SSD). The SSD was dy-
namically varied using four independently tracking staircases (two
staircases for stop trials with a leftward pointing Go stimulus and two
staircases for stop trials with a rightward pointing Go stimulus) to
achieve a successful stopping probability of approximately 50% (Aron
and Poldrack, 2006). Two staircases were selected per hand to ensure
subjects do not predict when a stop signal would occur. The initial
SSDs were 150 ms and adjusted in steps of 50 ms, reducing for failed
stop trials and increasing for successful stop trials. Subjects were
instructed to be as quick and accurate as possible and to do their best
to stopwhen a stop signal occurred (even though this would not always
be possible). There was a blank screen in the inter trial interval, which
was jittered between 1 and 1.4 s.
Table 1
Patient clinical characteristics.
Patient ID Age/gender/
handedness
Disease duration
(years)
Medications Dose
(mg)
Frequency
(times/day)
Hours since
medication (On)
Hours since
medication (Off)
UPDRS IIIa
(On)
UPDRS IIIa
(Off)
1 52/f/r 9 Lev 25/100 3 1.75 12.5 33 43
LevR 25/100 or 1 1.75 12.5
Rop 4 1 1.75 12.5
Am 100 2 1.75 12.5
Ras 1 1 1.75 12.5
2 67/f/r 2 Lev 25/100 3 4 13 22 28
Ras 1 1 4 13
3 55/f/r 12 Lev 25/100 2.5 3.5 13 16 32
Ras 1 1 1.5 13
4 62/f/r 8 Lev 25/100 1–3 3 12 34 40
5 74/m/r 1 Lev 25/100 4–6 1.5 15 44 47
Ras 1 1 1.5 15
Rop 8 4 1.5 15
6 71/f/r 1 Lev 25/100 3 3 14 20 20
Ras 1 1 11.5 13
7 62/m/r 2 Lev 25/100 3 2.75 13.5 54 49
Ras 1 1 2.75 13.5
Pr 1 1 2.75 13.5
8 63/m/r 2 Ras 1 1 5 24 31 38
RopXL 8 1 4 24
9 53/m/r 11 Lev 25/100 8 2.5 16 49 75
LevR 25/100 4 2.5 16
Rop 2 12 2.5 16
Sel 1 1 2.5 16
Am 100 2 2.5 16
10 74/m/r 2 Lev 100 3 2.5 17 27 32
Ras 1 1 2.5 17
11 55/m/r 2 Lev 25/100 3 2.5 16 30 30
Rop 12 1 2.5 25.5
Ras 1 1 2.5 25.5
12 69/f/r 6 Sel 5 2 2.5 13 30 38
Pr 1.5 3 2.5 13
13 47/m/r 6 Sel 1 1 3.25 13 42 58
RopXL 12 1 3.25 25
14 66/f/r 3 Lev 25/100 3 2 12.5 36 44
Ras 1 1 2 12.5
Pr 1 1 2 12.5
15 71/f/r 3 Lev 25/100 4 2.75 13 25 42
Ras 1 1 2.75 13
16 61/m/r 9 Lev 25/100 6 3 16 46 48
LevR 25/100 1 3 27
RopXL 8 & 12 1 & 1 3 27
Ras 1 1 3 27
Ent 200 6 3 27
Note:Medication names:Am—Amantadine, Ent— Entacapone, Lev—Carbidopa/levodopa (regular formulation), LevR—Carbidopa/levodopa (sustained release), Pr— Pramipexole, Ras—
Rasagiline, Rop — Ropinirole, RopXL— Ropinirole (extended release), Sel — Selegiline.
a UPDRS III score range is 0–108. Higher scores reﬂect greater impairment.
Table 2
Demographic and rating scale measures.
PD patients
N = 16
Controls
N = 16
Age (years) 62.62 (8.32) 63.50 (9.66)
Sex 8f 9f
Handedness All R All R
MMSE 28.94 (1) 29.19 (1.10)
NAART 46 (6.27) 49.12 (7.14)
BDI a 3.27 (3.20)
Off medication 9.44 (5.07)
On medication 7.76 (5.05)
UPDRS III b N/A
Off medication 41.5 (12.95)
On medication 33.68 (10.86)
Note: All values are given as mean (standard deviation).
MMSE, Mini-Mental Status Exam; NAART, North American Adult Reading Test; BDI, Beck
Depression Inventory, UPDRS, Uniﬁed Parkinson's Disease Rating Scale.
a BDI Patients Off andOnversus controls, t27 = 3.05, P b 0.01 and t30 = 4.25, P b 0.005
respectively.
b UPDRS III Patients Off versus On, t15 = 4.00, P b 0.005.
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feedback given. Prior to EEG recording, subjects were trained on a
short block of 40 trials.
2.4. EEG recordings
EEG was recorded using a 32 channel ActiveTwo (Biosemi Instru-
mentation system) using a sampling frequency of 512 Hz. Two extra
electrodes were placed over left and right mastoids, used for reference
and two electrodes were placed lateral and below the left eye for verti-
cal and horizontal electro-oculogram.
2.5. Analysis
2.5.1. Behavior for the stop-signal task
The following behavioral indices were estimated: correct go RT
(reaction time on correct Go trials), failed stop RT (reaction time on
stop trials when the subject failed to stop), percent go discrimination
errors (percentage of trials where the subject pressed the button box
on the wrong side), percent go omission errors (percentage of trials
where the subject failed to respond onGo trials), probability of stopping
Fig. 1. Stop-signal task: Each trial beganwith a ﬁxation cross, followed 500 ms later by the
appearance of a white square (Go signal). The square appeared to either the left or the
right of the ﬁxation cross requiring a response from the corresponding hand. Stop trials
were identical to Go trials, except theywere less likely (33% of trials) and thewhite square
turned red after a variable delay (stop signal delay).
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ping), overall SSD (mean SSD from the four staircases), and integration
SSRT (Stop Signal Reaction Time using the integration method (Logan
and Cowan, 1984; Verbruggen et al., 2013)).
2.5.2. EEG preprocessing
This was highly similar to our previous study (see Swann et al.
(2011)) and was performed using a combination of custom MATLAB
scripts and EEGLAB (Delorme and Makeig, 2004). It consisted of
referencing to mastoids, ﬁltering between 0.05 and 50 Hz, performing
independent component analysis denoising to remove eye and muscle
artifacts and visual inspection to ensure clean data. For the resting
state EEG data, to reduce the spurious effects of volume conduction on
pairwise coherence between electrodes (Greenblatt et al., 2012;
Winter et al., 2007), current source density estimates were evaluated
using a spherical spline algorithm (Perrin et al., 1989) implemented in
the MATLAB ‘CSD toolbox’ (Kayser and Tenke, 2006).
2.5.3. EEG analysis, resting state
Three minutes of EEG data were epoched into windows of 5 s each.
Power spectrum estimates of these epochs were evaluated using the
Fast Fourier Transform, after multiplying by a Hamming window. Mean
power was estimated in the frequency bands delta (0–4 Hz), theta (4–
8 Hz), alpha (8–13 Hz), beta (13–30 Hz) and gamma (30–50 Hz).
Coherence analysis was performed using complex Gaussian ﬁlters
with center frequencies between 0 and 50 Hz. 32 such ﬁlters were se-
lected with varying time and frequency bandwidths, consistent with
prior studies (Canolty et al., 2007; Swann et al., 2011) and also with
the approach taken for event-related time-frequency analysis of
the stop-signal task (see below). Absolute values of coherence ‘Coh’
were evaluated using the expression Coh t; fð Þ ¼ Wxy t; fð Þj j√Wxx t; fð Þ√Wyy t; fð Þ where
Wxy t; fð Þ ¼ 1N∑
N
k¼1
Wx t; fð Þ W⁎y t; fð Þ is the analytical signal of channel x
after ﬁltering, W⁎x(t,f) is its complex conjugate, Wxx(t,f) is the auto-
spectra of channel x, Wxy(t,f) is the cross-spectra of channels x and y,
and N is the number of epochs. These coherence values were then nor-
malized using Fisher's z-transform. The ﬁnal coherence values were av-
eraged over the entire time duration (except for epochs affected by
artifacts) to obtain one coherence value per channel pair for eachGauss-
ian ﬁlter for each subject (i.e. Cohfn1,n2 where n1 and n2 are the channelnumbers and f is the center frequency of the Gaussian ﬁlter). This was
performed for all pair-wise combinations of the 32 channels.
The relationship between a patient's coherence values in these fre-
quency bands (Cohfn1,n2) and clinical state (obtained from UPDRS)
was evaluated using Pearson's correlation coefﬁcient (r). The total num-
ber of these signiﬁcant pairs (out of the 32 channel combinations) was
used to deduce which frequency bands were most associated with clin-
ical impairment or improvement.
2.5.4. EEG analysis, stop-signal task
Time-frequency analysis was performed using the same Gaussian ﬁl-
ters used in the coherence analysis for the resting state EEG. The analysis
was similar to prior studies (Canolty et al., 2007; Swann et al., 2011). In
brief, the EEG data were time-locked to events corresponding to all stop
trials (successful and failed combined); this was performed to increase
statistical power of our analysis (although see below for a key analysis
which analyzed successful and failed stop trials separately). The data
were then ﬁltered using the Gaussians to obtain the analytic signal, the
absolute value of which was taken at each timepoint for each of the 32
center frequencies. These were then corrected to a baseline which
consisted of 500 ms in the inter trial interval. The data were then aver-
aged over trials for each condition (e.g. all stop trials) to create an aver-
aged event-related time-frequency map for that condition for each
channel. Based on other EEG results with the stop signal task
(Schmajuk et al., 2006; Swann et al., 2011), time-frequency maps were
averaged over a right frontal electrode cluster (F8, FC6) for each subject.
For evaluating the signiﬁcance for each condition within each group;
one sample t-tests were used at each time-frequency point. For testing
between group differences, paired sample t-tests were used between pa-
tients' On and Off sessions and unpaired sample t-tests between the high
and low improvement groups. The normality of these baseline-corrected
time-frequency points was evaluated using the Shapiro Wilk test.
3. Results
3.1. Resting state EEG
Earlier studies have shown that coherence is greater in the Off vs. On
medication state, and in particular, that this effect is greatest for those
patients who have higher (worse) UPDRS scores (Silberstein et al.,
2005). Accordingly, for each pair of electrodes, and in each frequency
band, we analyzed the correlation of the mean coherence (Cohfn1,n2)
with the subject's UPDRS score (Silberstein et al., 2005; Stoffers et al.,
2008). A sample estimation of this correlation for one of the Gaussian ﬁl-
ters for patients Off medication is shown in Fig. 2A. This correlation is
evaluated similarly for all possible pairs of the 32 electrodes (496
pairs) (Fig. 2B) and the number of positively correlated signiﬁcant pairs
was selected (Fig. 2C). This number was expressed as a percentage and
this estimation was repeated for each of the Gaussian ﬁlters (Fig. 2D).
For patients Off medication, this analysis revealed positive correla-
tions in the higher frequencies, with the beta frequency band in partic-
ular having the largest number of signiﬁcant pairs (Fig. 2D/E Off
condition). Thus, increases in coherence correlated with disease severi-
ty. For patients On medication, this cortical coherence was reduced
(Fig. 2E On condition). Further, the reduction was greatest in those pa-
tientswho improved themost on theUPDRS.We tested this by correlat-
ing the medication-related difference in pairwise coherence (Cohfn1,n2
Off–On) with the medication-related change in UPDRS scores (UPDRS
Off–On) for each subject in each frequency band. We observed that
more pairs were positively correlated at the higher frequencies (includ-
ing beta) signifying greater reductions in coherence in proportion with
clinical improvement (Fig. 2E Off–On condition). This shows that med-
ication reduces the pathological ‘locking’ at the cortex, especially in the
beta and gamma bands.
For completeness, we examined power spectrumeffects. Therewere
increases in power in the lower frequencies, also commonly referred to
Fig. 2. Correlation between scalp-level coherence and UPDRS scores. A. An example plot of coherence values at f = 21.1 Hz (beta) Gaussian frequency ﬁlter for channels 7 and 18
(Coh21.17,18) plotted vs UPDRS for each subject (15 subjects) in the Off medication condition resulting in a Pearson correlation coefﬁcient, r = 0.51 and signiﬁcance, P = 0.02. B. Grid
for 32 channels in beta band (f = 21.1 Hz) showing correlation (r) of pair-wise coherence with UPDRS per subject, red indicating positive correlation and blue indicating negative cor-
rection. C. Grid for 32 channels in beta band (f = 21.1 Hz) showing signiﬁcant correlation pairs at P b 0.05. D. The total number of signiﬁcant positively correlated pairs in the Off med-
ication state computed at each of the individual Gaussian frequency ﬁlters (where e.g. 18% signiﬁcant pairs at 30 Hz means that 18% of all the 496 possible pairs showed a signiﬁcant
correlation, across subjects, between coherence and UPDRS score). E. The total number of signiﬁcant positively correlated pairs computed at each of the individual Gaussian frequency
ﬁlters of Off Medication state (left lower panel; same as Panel D), On medication state (middle lower panel) and the Off–On difference (right lower panel). Those patients with greater
clinical impairmenthad stronger coherence in theOff state,withmore pairs positively correlated in the beta band. The correlation between coherence values andUPDRS scores for patients
isweaker Onmedication. The reduction in coherence in beta and gamma bandswithmedication is strongest in those patients who show the greatest clinical improvement, where positive
correlations indicate that greater reductions in coherence correspond to greater clinical improvement as indicated by the UPDRS scores.
Table 3
Stop-signal task behavioral performance.
Controls Patients
On medication Off medication
Go RT (ms) 518.77 (108.79) 528.41 (98.97) 523.09 (98.04)
Failed Stop RT (ms) a 459.94 (94.66) 462.78 (81.95) 453.89 (73.48)
Go discrimination error (%) b 0.37 (0.41) 1.17 (1.02) 0.49 (0.53)
Go omission error (%) 0.12 (0.20) 0.97 (2.02) 0.23 (0.44)
Prob. stopping overall (%) 50.36 (2.86) 49.08 (5.69) 51.93 (3.99)
Overall SSD (ms) 264.80 (109.87) 242.83 (102.32) 236.02 (84.43)
Integration SSRT (ms) c 246.04 (25.78) 267.90 (43.32) 269.78 (35.43)
Note: All values are given asmean (standard deviation). GoRT, reaction time on correct Go
trials; failed stop RT, reaction time on stop trialswhen the subject failed to stop; percent go
discrimination errors, percentage of trials where the subject pressed the button box on the
wrong side; percent go omission errors, percentage of trials where the subject failed to
respond on Go trials; Probability of stopping overall, percentage of stop trials where
subject was successful in stopping; overall SSD, mean SSD from the four staircases, and
integration SSRT.
a For each group, failed stop RT is faster than Go RT, consistent with a valid context
dependent horse-race model.
b Go discrimination error controls vs PD On, t30 = 3.86, P b 0.01; Go discrimination
error PD On vs PD Off, t15 = 2.46, P b 0.05.
c Integration SSRT controls vs PD On, t30 = 2.07, P b 0.05; Integration SSRT controls v
PD Off, t30 = 2.47, P b 0.05.
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more theta compared to controls at occipital electrodes (see Inline Sup-
plementary Fig. S1). We also observed a decrease in beta and gamma
power particularly at the frontal channels, although this effect was not
signiﬁcant. We did not observe any signiﬁcant differences between pa-
tients On and Off their medication in any particular frequency band (see
Inline Supplementary Fig. S1).
Inline Supplementary Fig. S1 can be found online at http://dx.doi.
org/10.1016/j.nicl.2013.07.013.
Thus, consistent with prior research (Silberstein et al., 2005; Stoffers
et al., 2008) our results show that while dopaminergic medication has
little effect onmodulating power at the cortex, it does successfullymod-
ulate intra-cortical coherence.
3.2. Stop-signal task
3.2.1. Behavioral results
The patients took signiﬁcantly longer to stop their responses than
controls as SSRT was longer (On vs. controls: t30 = 2.07, P b 0.05; Off
vs. controls: t30 = 2.47, P b 0.05). However, there was no difference
in SSRT for On vs. Off (P N 0.6) (Table 3; Fig. 3B). Thus, dopaminergic
treatment did not improve the patients' stopping ability.
On other indices, performance between the groupswas similar, with
no signiﬁcant differences for correct Go RTs (Fig. 3A), except for the dis-
crimination accuracy on Go trials (i.e. making the correct response),
where patients On medication made more errors than controls (t30 =
2.86, P b 0.01) and more errors than patients Off medication (t15 =
2.46, P b 0.05).
3.2.2. EEG time-frequency results
These were analyzed for the right frontal cluster (electrodes F8 and
FC6), time-locked to the stop signal. As predicted from our prior ﬁnd-
ings (Swann et al., 2011), therewas a relative increase in beta (althoughhigher beta (N20 Hz) in this study) at the time of stopping in the On
group and the Off group and also in controls; however, this increase
did not reach signiﬁcance relative to the inter trial interval baseline in
any group (see Inline Supplementary Fig. S2). Although the weak effect
in controlswas surprising (see Discussion below)we note that themain
objective of this study was to examine the effect of medication. Conse-
quently we focus on the patients henceforth.
Inline Supplementary Fig. S2 can be found online at http://dx.doi.
org/10.1016/j.nicl.2013.07.013.
Fig. 3. Stop signal task results A. Mean Go RTs for controls and patients On and Off medi-
cation. There is no signiﬁcant difference between the groups. B. Mean SSRTs for controls
and patients On andOffmedication. There are signiﬁcant differences between the controls
and patients On medication (t30 = 2.07, P b 0.05); as well as between the controls and
patients Off medication sessions (t30 = 2.47, P b 0.05).
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related with the individual patient's clinical improvement (measured
by the UPDRS) (Fig. 2), the stopping-related data were further exam-
ined by dividing the patients into two groups based on a median split
of clinical improvement indicated by the difference in UPDRS scores
(Off–On). Eight patients formed a ‘high-improvement’ group and
seven a ‘low-improvement’ group.
First, we examined behavior by using a mixed model repeated mea-
sures ANOVA to test the effect of medication On vs Off for high vs low
improvement groups. Surprisingly, this did not reveal any signiﬁcant
main effects of group or interactions between group and medication
(see Inline Supplementary Table S1). Nevertheless, there was a notable
group difference in the EEG.We observed a stopping-related increase in
beta and gamma band power in the right frontal cluster in the high-
improvement group (especially when On medication), but less for the
low-improvement group (Fig. 4A, B). Within the high improvement
group, there was strongly elevated stopping-related beta and gamma
for On vs. Off; however, this was not the case in the low improvement
group (Fig. 4C). Finally, the interaction ‘high vs low’ improvement and
‘On vs Off’medication was signiﬁcant (P b 0.05) (Fig. 5) (This was esti-
mated by performing an unpaired sample t-test of the On minus Off
time-frequency maps of high and low improvement groups). Notably,
this increase was not only for all stop trials taken together but also for
the subset of successful stop trials, thus obviating the concern that it
could have been driven by relative differences in desynchronization
on failed stop trials or an effect of the movement itself. In addition, we
compare this result for the successful stop trials for the right frontal
cluster with the equivalent left frontal cluster (F7, FC5) (Inline Supple-
mentary Fig. S3). We observed a greater increase in beta in the right
frontal cluster compared to the left cluster around the time of stopping.
Inline Supplementary Table S1 and Fig. S3 can be found online at
http://dx.doi.org/10.1016/j.nicl.2013.07.013.
To map the spatial extent of this effect, we inspected the mean beta
frequency t-score values of this interaction (‘high vs low’ improvement
and ‘On vs Off’medication) as a topography map (Fig. 6A); averaged in
time segments of 200 ms. Therewas an increase in beta in a right frontalcortical locus and at a time range (aroundSSRT) consistentwith our ear-
lier study for patients On vs Off STNDBS (Swann et al., 2011). As a com-
parison, we also inspected the same beta frequency interaction for
successful Go trials time-locked to the button press (Fig. 6B) (Also see
Inline Supplementary Fig. S4). There was an increase around the time
of the button press and extending post-movement, but this increase
was concentrated in the sensorimotor rather than frontal regions.
Inline Supplementary Fig. S4 can be found online at http://dx.doi.
org/10.1016/j.nicl.2013.07.013.
4. Discussion
We studied PD patients whowere On and Off dopaminergic therapy
using both resting state EEG and an executive control taskwith EEG. For
the resting state EEG, when patients were Off medication, there was
strong pair-wise scalp coherence in the beta band, especially for the pa-
tients with greater clinical impairment. Dopaminergic therapy reduced
this pathological synchronization, in proportion with clinically relevant
improvement (UPDRS scores), especially in the beta and gamma bands.
For the stop-signal task, the patients were behaviorally impaired in
stopping compared to controls, but medication did not remediate this.
Based on the resting state EEG results, we split the patients into those
with higher and lower clinical improvement (UPDRS) for On vs. Off
medication. EEG analysis showed a frontal beta band increase at the
time of stopping for the high improvement groupwhen On vs. Off med-
ication, and this medication induced task-related increase was signiﬁ-
cantly greater than for the low improvement group. Notably, for Go
trials there was also a beta band increase, but it was more over sensori-
motor than frontal regions, possibly pointing to dissociable effects on
different fronto-basal-ganglia circuits for stopping and going. Taken to-
gether, the main results show that for the patients who beneﬁted the
most from medication, there was a reduced pathological cortical syn-
chronization in the beta band in the resting state and also increased
task-related beta band power for stopping at a right frontal focus and
for going over sensorimotor cortex.
4.1. Dopaminergic medication reduces pathological coherence at the scalp
With resting state EEG, we showed that those patients with the
greatest clinical impairment had the strongest beta band coherence be-
tween cortical areas when Off medication, and also that those patients
who beneﬁted the most from medication (evaluated with UPDRS)
showed the greatest reduction in this coherence. This is consistent
with Silberstein et al. (2005) who also observed that medication-
induced changes in beta band coherence correlated with clinical im-
provement. The opposite effect was observed in an MEG study
(Stoffers et al., 2008), although in a further analysis, a subset of patients
did show decreases in beta coherence with medication (Stam, 2010;
Stoffers et al., 2008).
Our results point to the efﬁcacy of dopaminergic medication in re-
ducing the pathological ‘locking’ at the cortex at frequencies such as
beta and gamma when patients are at rest. It is important to note that
this change in coherence occurred despite the fact that there were no
signiﬁcant differences in power in these frequency bands for On vs.
Off medication. This is consistent with prior reports of medication-
related coherence change without changes in power (Brown, 2007;
Stam, 2010; Stoffers et al., 2008). One aspect of the ﬁnding is counter-
intuitive, namely, medication also reduced coherence in the gamma
band. This is puzzling because gamma has been considered pro-kinetic
in PD,whereas beta is antikinetic (Brown, 2003), and thuswewould ex-
pect an increase rather than a decrease in coherence in the gamma band
when Onmedication. However, Silberstein et al. (2005) also reported a
reduction in resting state gamma band cortical coherence On dopami-
nergic medication (but no reduction following STN DBS). It remains to
be determined howdopaminergic drugs and deep brain stimulation dif-
fer in this regard.
Fig. 4. Beta and gamma band power of right frontal cortex is increased for stop trials in the high improvement group. A. All stop trials (successful and failed combined) for the On med-
ication condition for high and low improvement groups. B. All stop trials for the Offmedication condition for high and low improvement groups. C. All stop trials for theOn vsOff between-
session comparison for high and low improvement groups. Time-frequency results are shown for the right frontal cluster (F8, FC6). Plots are generated from trials time-locked to the stop
signal, here corresponding to 0 ms. T-score signiﬁcance values are displayed as color; t-score values reach signiﬁcance at t7 = 2.36 (high improvement group) and t6 = 2.44 (low im-
provement group). Signiﬁcance at P b 0.05 is outlined in black indicating positive direction and red indicating negative direction.
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The observation above that medication reduced cortical coherence
in the beta band, especially in those patients who showed the greatestFig. 5.Medication increases right frontal beta band power for stoppingmore in the high than lo
for On vs Off medication for the high vs low improvement group comparison. There is a signiﬁca
time of SSRT. Time-frequency results are shown for the right frontal cluster (F8, FC6). Plots are
signiﬁcance values are displayed as color. T-score signiﬁcance values are displayed as color; t-s
niﬁcance at P b 0.05 is outlined in black indicating positive direction and red indicating negaticlinical improvement, raises the possibility that medication had its ef-
fects by ameliorating impaired cortico-basal-ganglia neural communi-
cation. Our analysis of the stop-signal task EEG data allowed us to test
this possibility. Based on our prior studies, we focused on a right frontalw improvement group. Successful stop and all stop (successful and failed combined) trials
nt increase in beta power starting from the time of the stop signal and peaking around the
generated from trials time-locked to the stop signal, corresponding to 0 ms here. T-score
core values reach signiﬁcance at t13 = 2.16 (high vs low and On vs Off comparison). Sig-
ve direction.
Fig. 6. Time and frequency averaged beta frequency t-score values for On vs Off medication for the high vs low improvement group comparison displayed as a topographymap. A. Successful
stop trials where 0 ms corresponds to the time of the stop signal. B. Successful Go trials where 0 ms corresponds to the time of the button press. Trials include Go stimulus that appeared on
both left and right. T-score signiﬁcance values are displayed as color; t-score values reach signiﬁcance at t13 = 2.16 (high vs low andOn vs Off comparison). Arrows point to critical regions of
increase; the increase in beta for stopping begins and is concentratedmore at the right frontal regions, in the time associatedwith stopping (0–400 ms). The increase in betawhile going and
post movement is concentrated more at the sensorimotor regions.
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(Swann et al., 2011). We hypothesized that communication within
this stopping network, observed from the scalp oscillations in the beta
band, would be stronger when patients were On compared to Off dopa-
minergic medication. Although this prediction was not born out when
comparing all patients Onwith all patients Off, it did emergewhen split-
ting the patients into high vs. low improvement groups, based on the
change in UPDRS scores with medication (and motivated by the resting
state EEG ﬁndings). Speciﬁcally, there was a signiﬁcant increase in right
frontal beta band power for the On–Off comparison between the high
and low improvement groups in a time range consistent with the stop-
ping process.
In addition to the right inferior frontal cortex, studies have shown
the involvement of motor cortices (M1 and PMc) in canceling initiated
limb movements (Coxon et al., 2006; Mattia et al., 2012; Mirabella
et al., 2011). In particular, it has been thought that these regions act as
the ﬁnal target of the inhibition commands generated by the putative
frontal-basal ganglia network (Mattia et al., 2012). It is difﬁcult to
make speciﬁc conclusions with respect to the regions given the limited
spatial resolution of scalp EEG, however, the topography maps of this
beta increase show frontal as well as motor regions (M1). Moreover,
this signiﬁcant increase was also observed for successful stop trials
and not just for all stop trials. Although we observed an increase in
beta for unsuccessful stop trials too, this increase was much smaller
than for successful stop trials.
Overall, these results provide further evidence for the importance of
the beta band for stopping within a putative fronto-basal-ganglia net-
work (Krämer et al., 2011; Marco-Pallarés et al., 2008; Swann et al.,
2011, 2012). Though we did not observe any differences in SSRT be-
tween patients On and Off dopaminergic medication, we did observe
changes in the EEG that were modulated by medication especially in
the patients with the greatest clinical improvement, and in a way that
was very similar to STN DBS. Taken together with our STN DBS report
(Swann et al., 2011) our results suggest that dopamine therapy also
modulates communication in a putative frontal-basal-ganglia circuit
that is important for stopping action, especially for the group of patients
who had the best response to medication.
We also show that beta-frequency is affected by medication during
and aftermovement (going), although thiswasmore over sensorimotorthan frontal regions. In particular, such beta-frequency effects have
been observed in sensorimotor regions for imagined or self-paced
movement— something that is also modulated by dopaminergic medi-
cation (Devos and Defebvre, 2006; Devos et al., 2003; Labyt et al., 2005;
Priori et al., 2002). These results suggest that dopaminergic medication
affects functionally distinct basal ganglia loops (a prefrontal/premotor-
basal-ganglia executive loop for stopping versus a premotor/primary
motor/basal-ganglia loop for going/movement). The results also high-
light the utility of using EEG in conjunction with behavioral approaches
to look at medication effects.
4.3. Limitations
The study was subject to several limitations. Firstly, for the resting
state EEG analysis, the correlation between the number of coherence
pairs and UPDRS was not signiﬁcant when corrected for multiple com-
parisons. However, our results, for beta frequency speciﬁcally, are a rep-
lication of Silberstein et al. (2005). Second, while Swann et al. (2011)
showed that STN DBS improved stopping behavior (faster SSRT for On
vs. Off stimulation) (and also see Mirabella et al., 2012; van den
Wildenberg et al., 2006) that was not the case here: SSRTwas very sim-
ilar for On vs. Off medication, although both were impaired (longer
SSRT) compared to controls. Notably, other stop signal studies in PD pa-
tients testing the effect of medication also reported no differences in
SSRT for On vs Off (Alegre et al., 2012; Obeso et al., 2011). Furthermore,
in our study even when we compared the high and low improvement
groups, there was still no difference in SSRT for On vs Off in either
group. This lack of medication effect on behavioral stopping is at odds
with our EEG ﬁndings that beta band power was strongly increased
over right frontal cortex when stopping in the high improvement
group and especially when On medication. This discrepancy could be
explained by differential sensitivity of behavior vs. electrophysiology
to the effects of medication. Further research is required to establish if
the observed beta band response in the task is causally important for
stopping, and whether medication would affect behavioral stopping in
a larger sample or in patients with a more uniform clinical and medica-
tion picture. Third, an anomalous aspect of this study was that the con-
trol subjects did not have a signiﬁcant increase in beta-frequency at the
time of stopping (although there was a numerical increase in the high
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or to baseline levels of beta power that could have weakened the ob-
served stopping-related response. Importantly, the main conclusions
of this report do not rely on a comparison of electrophysiological re-
sponses between patients and controls. Fourth, while the main EEG re-
sult of a right frontal beta band increase around the time of stopping for
the high versus low improvement group and especially for On medica-
tion was signiﬁcant at the individual time-frequency point level, it was
not when correcting for all possible comparisons. However, the fre-
quency band and timing of this effect are highly consistent with prior
studies (Krämer et al., 2011; Marco-Pallarés et al., 2008; Swann et al.,
2011, 2012). In addition, the beta frequency behavior for the high and
low improvement groups that we observe during stopping, that is a de-
crease followed by an increase, is also similar to that seen in the STN
while performing a similar task (Alegre et al., 2012; Ray et al., 2012);
though interpretations of this beta vary between differences in going
for successful stop trials, an active inhibitory process, or a mixture of
both. Fifthly, in this studywe ﬁltered the data to 50 Hz and thus restrict-
ed our analysis till the lower gamma range (30–50 Hz). It may be possi-
ble for further studies to study the effects of medication at higher
gamma both for rest and for task related EEG. Finally, in this study, the
stop signal task was always followed by the resting state. During a
pilot study with older controls, we observed that having the resting
state EEG ﬁrst introduced some tiredness, though the duration was
only 3 min, and hence these tasks were not counterbalanced.
5. Conclusion
Dopaminergic medication reduced resting state EEG beta coherence
and increased task-related beta power for PD patients who had the
greatest clinical improvement. This bolsters earlier reports of the impor-
tance of the beta band for communicationwithin a putative fronto-basal
ganglia circuit for inhibitory control. It is also consistent with an earlier
report showing that STN DBS On vs. Off also modulated right frontal
beta band power in the same way. However, although STN DBS did im-
prove stopping behavior, dopaminergic medication did not. Additional-
ly we observed a change in beta over sensorimotor regions for going
which was also modulated by medication. The results argue for the im-
portance of electrophysiology over and above pure behavior for testing
hypotheses about the effect of dopaminergic medication on higher cog-
nitive functions. Overall, the results advance the understanding of the
clinical pathophysiology of PD, the effects of dopaminergic drugs on cor-
tical oscillations and on the implementation of inhibitory control. Spe-
ciﬁcally, we interpret the ﬁndings as showing that medication reduces
pathological ‘locking’ at the cortex, thus enabling improved information
transfer in cortico-basal ganglia circuits.
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